Bayer Raises 2026 Profit Forecast as Pharmaceutical Division Exceeds Expectations

The given news headline concerns Bayer and does not directly relate to GOOGL (Alphabet) stock; therefore, the news impact on GOOGL is largely neutral. Technical indicators point to significant weakness: a sharp 13.9% decline over the last 24 hours, RSI14 at 30.5 near the oversold threshold, and the price remaining below both SMA20 and SMA50 indicate that short-term pressure persists. Although MACD is in negative territory, it is above the signal line (macd > signal), suggesting a slight recovery signal. Under these conditions, it is difficult to determine a news-driven direction; current price action increases the likelihood of a sideways-volatile course or rebound buying in the short term. Nevertheless, due to oversold conditions, the possibility of a short-term technical rebound should not be ignored.

Bayer's upward revision of its 2026 profit forecast and the pharmaceutical division's better-than-expected performance are fundamentally positive catalysts. However, the price has already risen 9.15% in 24 hours and RSI14 at 77.98 places it in overbought territory, increasing the risk of short-term profit-taking. MACD is slightly below its signal line (0.264 vs 0.293), signaling weakening momentum. The price is trading above SMA20 and SMA50, with the trend direction upward. Although the news is positive, due to overbought conditions, the 1-3 day impact is expected to be limitedly positive.